Equities analysts expect that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will post $563.53 million in sales for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Jazz Pharmaceuticals’ earnings, with estimates ranging from $546.48 million to $573.20 million. Jazz Pharmaceuticals reported sales of $476.46 million in the same quarter last year, which indicates a positive year-over-year growth rate of 18.3%. The company is expected to issue its next earnings report after the market closes on Tuesday, February 25th.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year sales of $2.15 billion for the current year, with estimates ranging from $2.13 billion to $2.16 billion. For the next year, analysts forecast that the firm will report sales of $2.37 billion, with estimates ranging from $2.24 billion to $2.47 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Jazz Pharmaceuticals.

Several research analysts have recently issued reports on the stock. SunTrust Banks restated a “buy” rating and set a price objective (up previously from ) on shares of Jazz Pharmaceuticals in a research report on Friday, January 31st. Wells Fargo & Co increased their price objective on shares of Jazz Pharmaceuticals from $186.00 to $189.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. ValuEngine downgraded shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, January 15th. TheStreet upgraded shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Friday, November 29th. Finally, Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, January 8th. They set a “neutral” rating and a $153.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $166.14.

Shares of NASDAQ JAZZ traded down $1.08 during midday trading on Tuesday, hitting $140.85. The stock had a trading volume of 315,706 shares, compared to its average volume of 465,099. The business’s 50 day moving average is $146.52 and its 200-day moving average is $137.40. The company has a market cap of $8.00 billion, a P/E ratio of 13.48, a PEG ratio of 0.76 and a beta of 1.18. Jazz Pharmaceuticals has a 52 week low of $116.52 and a 52 week high of $154.24. The company has a quick ratio of 3.71, a current ratio of 3.89 and a debt-to-equity ratio of 0.56.

In other news, VP Patricia Carr sold 1,749 shares of the stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $148.93, for a total value of $260,478.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 1,250 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $149.61, for a total transaction of $187,012.50. Following the completion of the sale, the chief executive officer now directly owns 300,138 shares of the company’s stock, valued at $44,903,646.18. The disclosure for this sale can be found here. Over the last three months, insiders sold 24,999 shares of company stock valued at $3,714,896. Corporate insiders own 4.30% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in JAZZ. MUFG Americas Holdings Corp purchased a new position in Jazz Pharmaceuticals during the third quarter valued at $29,000. CI Investments Inc. grew its stake in Jazz Pharmaceuticals by 846.2% during the fourth quarter. CI Investments Inc. now owns 246 shares of the specialty pharmaceutical company’s stock valued at $37,000 after acquiring an additional 220 shares in the last quarter. AdvisorNet Financial Inc purchased a new position in Jazz Pharmaceuticals during the third quarter valued at $37,000. Trustcore Financial Services LLC grew its stake in Jazz Pharmaceuticals by 52.6% during the fourth quarter. Trustcore Financial Services LLC now owns 290 shares of the specialty pharmaceutical company’s stock valued at $43,000 after acquiring an additional 100 shares in the last quarter. Finally, CWM LLC grew its stake in Jazz Pharmaceuticals by 156.3% during the third quarter. CWM LLC now owns 323 shares of the specialty pharmaceutical company’s stock valued at $41,000 after acquiring an additional 197 shares in the last quarter. 89.15% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: Real Estate Investment Trust (REIT) ETF

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.